** Shares of medical diagnostics co Lantheus Holdings LNTH.O fall 7.4% to $91.03
** LNTH says it will buy Evergreen Theragnostics to expand its oncology radiopharmaceutical pipeline with multiple experimental cancer treatments
** Deal consists of an upfront payment of $250 mln and up to $752.5 mln in milestone payments to Evergreen
** JonesTrading analyst Justin Walsh says current weakness in LNTH is due to concerns about the co deploying cash on acquisitions that are expected to add to EPS only ~18 months post-close; he believes this market reaction is "wholly unwarranted"
** Deal expected to close in H2 2025
** 12 of 13 brokerages rate the stock "buy" or higher and 1 "hold"; their median PT is $135 - LSEG
** LNTH gained 41.8% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.